Articles tagged with Alzheimer Disease
Researchers developed a synthetic compound called CPTX that improved symptoms of Alzheimer's disease, spinal cord injury, and cerebellar ataxia in mice. The protein restored neural connections, increased excitatory transmission, and promoted memory formation.
Researchers developed an AI algorithm that can accurately diagnose Alzheimer's without expensive scans or in-person testing, with over 95% accuracy. The software also explains its conclusions, allowing physicians to double-check the accuracy of its diagnoses.
Women with Alzheimer's live longer and experience less severe symptoms due to the protective effects of their second X chromosome. The study found that women carrying a specific variant of the KDM6A gene have twice the dose of protective proteins, giving them greater protection against the disease.
A new therapeutic approach to treating Alzheimer's disease has been discovered by researchers at the University of Kentucky, using an antibody to target inflammation and promote microglia to clear amyloid deposits in the brain. The study found that this approach leads to reduced amyloid deposition and improved cognition.
Researchers have identified a new form of dementia, LATE disease, which shares symptoms with Alzheimer's but is caused by different brain processes. The study provides criteria to differentiate between frontotemporal dementia and LATE disease, offering hope for future therapy development.
Researchers analyzed genetic studies and found no causal link between sleep patterns and Alzheimer's disease. However, they discovered a small association between certain sleep characteristics and increased or decreased risk of developing Alzheimer's, including being a 'morning person' and having lower insomnia risk.
Researchers found that brain function remapping is impaired in Alzheimer's disease patients, causing spatial memory impairment. Improving brain remapping function may reverse spatial memory impairment using deep brain stimulation methods.
A new study identifies two genes, TMEM106B and RBFOX1, that regulate gene expression in the aging brain and are linked to both Alzheimer's disease and Limbic-predominant Age-related TDP-43 Encephalopathy (LATE). The findings suggest a shared molecular basis for these diseases, which may lead to new treatments and prevention strategies.
Researchers identified the LANDO pathway as a key factor in neuroinflammation, which is a major hallmark of Alzheimer's disease. By disrupting this pathway, scientists found that they could reduce neuroinflammation and even improve cognition and memory in a mouse model.
Neurodon, a Purdue University-affiliated startup, has received a $2 million NIH grant to develop targeted neuroprotective molecules for Alzheimer's disease. The molecules have shown promise in preserving calcium ion balance and offering a new therapeutic strategy for neurodegeneration.
Scientists at DGIST discovered that specific proteins in nasal discharge can indicate the onset and progression of Alzheimer's disease, providing a novel approach for early detection. The levels of two particular Aβ oligomers were consistently higher in patients with AD, allowing for non-invasive screenings to assess AD progression.
Researchers at Korea Brain Research Institute used GANs to analyze bulk RNA-seq data, finding that increased Amyloid-beta in the brain alters cholesterol biosynthesis. This study provides a new approach for projecting biological changes and aiding healthcare industry.
Research suggests that increasing levels of education may be protective for people with a gene for familial early onset Alzheimer's, delaying the development of amyloid plaques. Participants with less than 10 years of education had twice as many plaques as those with more than 16 years.
A new study published in Redox Biology shows that the drug CMS121 successfully reversed memory loss in a mouse model of inherited Alzheimer's disease. The drug works by normalizing lipid peroxidation and lowering levels of fatty acid synthetase, suggesting FASN as a potential target for treating Alzheimer's disease.
Researchers at Tokyo University of Science used infrared laser irradiation to destroy amyloid fibrils, which are typical of neurodegenerative diseases like Alzheimer's. The study combines experimental and simulation results, showing that the process begins at the core of the fibril, where resonance breaks intermolecular hydrogen bonds.
Researchers have identified measurable Alzheimer's risk factors in adolescents and young adults, emphasizing the need for early interventions targeting heart health and education. Studies found that high blood pressure, diabetes, and poor educational quality are associated with worse late-life cognition, particularly in African Americans.
Countries in US, Europe struggle with funding, workforce shortages, and technology limitations to address growing demand for Alzheimer's disease treatment. Despite these challenges, initiatives like telehealth models and memory clinics are being implemented to improve access to care.
A phase 3 trial found pimavanserin to be effective in reducing psychotic symptoms in people with dementia, regardless of underlying dementia subtype or severity. The treatment works differently than other antipsychotics, showing promise for improving the lives of those affected by psychosis.
Researchers discovered deposits of the tau protein typically found in Alzheimer's patients in the brain of an autistic child with ADNP syndrome. An experimental drug called NAP successfully restored normal function to damaged nerve cells in models of ADNP syndrome, offering new hope for treating this genetic disorder.
A new blood test has demonstrated remarkable promise in discriminating between individuals with and without Alzheimer's disease. The test measures phospho-tau217, a protein found in tau tangles, and shows great accuracy in detecting the disease, even in its early stages.
A new study from the University of Sheffield reveals that artificial intelligence (AI) can detect neurodegenerative disorders like Alzheimer's before progressive symptoms worsen. AI-powered technologies can help predict disease progression and suggest the best treatments for individual patients.
A study compared the diagnostic accuracy of a blood biomarker tau phosphorylated at threonine 217 (P-tau217) with other biomarkers for distinguishing Alzheimer's from neurodegenerative diseases. The results showed that P-tau217 had high sensitivity and specificity, making it a promising tool for early diagnosis.
A blood test for Alzheimer's disease has shown high accuracy in detecting the disease, with levels of p-tau217 increasing seven-fold in individuals with Alzheimer's. The test detected tau brain changes 20 years before cognitive impairment in those with a genetic predisposition.
A new study has uncovered 12 proteins linked to both tau and Alzheimer's disease, expanding understanding of the molecular interactions driving neurodegeneration. The research analyzed donated brain tissue samples from individuals with Alzheimer's, revealing dozens of other proteins associated with the disease.
Two studies indicate that WTC responders are at risk for developing dementia, with reduced gray matter thickness in the brain consistent with neurodegenerative conditions. Researchers found protein changes in blood consistent with Alzheimer's disease in responders with PTSD and mild cognitive impairment.
Researchers at UArizona Health Sciences are developing a novel treatment for Alzheimer's disease by targeting the DYRK1A enzyme. This approach aims to prevent or reverse the progression of the devastating neurodegenerative disorder. Preliminary tests have shown significant reductions in cognitive decline and disease development.
A new study published at the 2020 Alzheimer's Association International Conference suggests that receiving at least one flu vaccination can lower the risk of developing Alzheimer's disease over a lifetime. The research found that people who received a flu vaccine were 17% less likely to get Alzheimer's disease.
Researchers discovered that low-concentration salt crystals can precipitate at nanoscales due to local density fluctuation, accelerating amyloid-β peptide aggregation. This process could provide a permanent solution for Alzheimer's disease treatment.
Research reveals flu vaccinations can reduce Alzheimer's incidence by up to 17%, with pneumococcal vaccination showing a similar protective effect. Vaccination also found to reduce mortality in people with dementia.
Researchers at Washington University School of Medicine have developed a technique to detect minute amounts of p-tau-217, a protein fragment linked to Alzheimer's disease in the blood. The levels of this protein are elevated during the early stages of the disease and can accurately predict the presence of amyloid plaques in PET scans.
Researchers validate sEH enzyme inhibition to reduce neuroinflammation, improve endogen response and neuronal damage in Alzheimer's disease. The study suggests sEH as a new therapeutic target with potential implications for other inflammatory pathologies.
A Purdue University team, led by Gaurav Chopra and Riyi Shi, received a $1.3 million grant to develop biomarkers and treatments for traumatic brain injury-related Alzheimer's disease and dementia. The researchers aim to improve understanding of microglial cell states in the context of TBI-related neurodegenerative dementia.
Experiences of racism among African Americans are associated with lower subjective cognitive function and increased risks of depression, poor sleep, type 2 diabetes, and hypertension. Research from the Black Women's Health Study found that women reporting higher levels of daily and institutional racism had a greater risk of poor SCF.
A study published in Neuron reveals how normal brain network function of hippocampus cells, which works to discriminate a distinct spatial environment, is disrupted in Alzheimer's disease. The disruption is likely caused by the activity impairment of the entorhinal cortex.
Scientists discovered oxytocin can reverse Aβ-induced impairments in mouse hippocampus, suggesting potential therapeutic option for Alzheimer's. Oxytocin's effect is mediated through oxytocin receptors, and blocking them eliminates its ability to reverse damage.
Researchers at Sanford Burnham Prebys Medical Discovery Institute have identified vitronectin, a blood protein, as a promising drug target for dry age-related macular degeneration. The study's findings suggest that vitronectin drives the formation of abnormal deposits that cause progressive vision loss.
Research identified 21 evidence-based suggestions for preventing Alzheimer's disease, with a focus on vascular risk factors and lifestyle modifications. Targeting factors such as cognitive activity, high blood pressure, depression, diabetes, and stress may help reduce the risk of developing Alzheimer's disease.
The AHEAD 3-45 study is a Phase III clinical trial aiming to prevent worsening memory and thinking among individuals at risk for future decline. Researchers hope to find that BAN2401 can help prevent Alzheimer's disease.
Researchers from Göttingen and Halle create novel inhibitors for enzymes involved in Alzheimer's disease, offering a promising new treatment approach. The study reveals a potential solution to the incurable nature of Alzheimer's disease through highly selective binding without harmful side effects.
Researchers at UT Health San Antonio have identified a new class of proteins that protect synapses from destruction. These proteins, called complement inhibitors, may offer a novel therapy for managing Alzheimer's disease and schizophrenia.
A small clinical trial found that higher doses of omega-3 supplements may be needed to make a difference in preventing cognitive decline. Participants with the APOE4 gene mutation showed lower increases in brain levels of omega-3s compared to those without it.
A study of 449 older adults found that individuals with subjective felt memory problems also exhibited measurable cognitive deficits associated with Alzheimer's disease. The findings suggest that early diagnosis and therapy development could benefit from these results.
A recent study by UNLV researchers found that while the success rate of Alzheimer's drugs in development remains low, there is increased hope due to repurposed agents and advancements in biomarkers. The team also emphasized the critical role of patient participation and the need for investment in new therapies.
A study supported by the Alzheimer's Drug Discovery Foundation found that rotigotine, a dopamine-acting drug, improved frontal lobe executive function and daily activities in patients with mild-to-moderate Alzheimer's disease. The treatment also enhanced dopaminergic pathways reaching this section of the brain.
A recent study has found that elderly Alzheimer's patients are more susceptible to COVID-19 infection due to increased expression of the ACE2 gene, which acts as an entry receptor for SARS-CoV-2. The research, published in the Journal of Infection, suggests that elevated ACE2 levels can lead to a higher risk of infection.
Researchers have identified a gene, TMEM106B, as a risk factor for neurodegenerative diseases such as Alzheimer's and frontotemporal dementia. The study found that a mutation in this gene disrupts the formation of myelin sheaths around nerve fibers, leading to neurological defects.
Researchers at Queen Mary University of London discovered a naturally suppressive gene that prevents Alzheimer's Disease in brain cells, leading to the development of a rapid drug-screening system. The system demonstrates proof-of-principle for early preventative-drug testing and identifies a potential biomarker for risk assessment.
Eugenia Trushina, Ph.D., Mayo Clinic Rochester researcher, receives $600,000 to develop new drug candidates restoring mitochondrial function in treating Alzheimer's. The ADDF-Harrington partnership aims to accelerate discovery into clinical studies for a potential cure.
Researchers are exploring how amyloid plaques degrade the brain's vascular system by impairing astrocytes, leading to a weakening of the blood-brain barrier. The study aims to pinpoint genes and proteins in astrocytes that contribute to Alzheimer's disease progression.
A new study suggests that misfolded protein build-up in the gut may contribute to Alzheimer's-like symptoms in mice, potentially leading to a new treatment approach targeting the gut. The researchers found that beta amyloid proteins injected into the gut traveled to the nervous system and brain, causing cognitive impairments.
Research suggests that antioxidant treatment after acute ischemic stroke could delay the onset of Alzheimer's dementia by reducing oxidative stress and promoting mitochondrial function. Studies have shown promising results with molecules like edaravone and nerinetide, but more research is needed to confirm these findings.
A new study reveals that the common asthma drug salbutamol may offer potential as a treatment for Alzheimer's disease. It is effective at reducing the accumulation of insoluble fibres of the tau protein, which are found in the brains of people with Alzheimer's disease.
A new study sheds light on the molecular factors that render entorhinal brain cells uniquely sensitive to degeneration. Researchers found that a suite of genes is likely involved in making these neurons easy targets for degeneration, with PTBP1 playing a major role.
Researchers found higher brain iron levels associated with cognitive deterioration in Alzheimer's disease, suggesting a potential role for iron chelators in treatment. Iron deposition was linked to amyloid beta and neurofibrillary tangles, disruptors of cell function.
Researchers discovered a key mechanism that triggers blood vessel stiffness, leading to cardiovascular disease. Re-purposed Alzheimer's drugs targeting BACE1 enzyme show promising results in reversing blood vessel damage.
Researchers found that neurons with high remodeling activity are more vulnerable to Alzheimer's disease and die when their remodeling goes awry. The study, which linked amyloid-beta and tau proteins at the genetic and molecular levels, provides insights into the disease's progression.
Researchers at Lund University have developed a 3D model of human hippocampal tissue from induced pluripotent stem cells, allowing for the study of early cellular dysfunction in Alzheimer's disease. The study found that patient-specific pathology differs between individuals with extreme symptomatology.
Researchers provide new understanding of co-aggregation process between proinflammatory S100A9 protein and Aβ42 peptide in Alzheimer's disease. The study reveals that S100A9 amyloids coat the surface of Aβ42 amyloids, reducing secondary nucleation sites and enhancing cellular toxicity.
The ApoE4 variant prevents the recycling of sortilin, a receptor that supplies neurons with essential fatty acids. This disruption leads to reduced lipid uptake and increased inflammation in brain cells, making them susceptible to cell death.
A recent study by the University of Kentucky's Sanders-Brown Center on Aging has identified a previously under-recognized form of dementia, quadruple misfolded proteins (QMP), linked to TDP-43 proteinopathy. The study found that about 20% of participants with dementia had QMP, resulting in the most severe dementia cases.